Arcus Biosciences RCUS
NYSE RCUS
$18.93 +0.65 (+3.56%)
At close: Nov 9, 2026 · 4:00 PM EST

Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024)

Updated

Analysis

Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Arcus Biosciences 2.42 Bn -713.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 20.00 Mn
API Access

Arcus Biosciences Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=RCUS&period=max&api_key=YOUR_API_KEY